Pulmonary fibrosis can complicate diverse pulmonary and systemic pathologies. In many
cases the underlying cause remains unidentified. Mortality from the disease is increasing …

Pulmonary fibrosis is the end stage of many diffuse parenchymal lung diseases. It is
characterised by excessive matrix formation leading to destruction of the normal lung …

Idiopathic pulmonary fibrosis (IPF) is a devastating condition that carries a prognosis worse
than that of many cancers. A recent classification of the idiopathic interstitial pneumonias …

Organ fibrosis, the result of exaggerated, persistent, and often irreversible accumulation of
extracellular matrix, complicates numerous diseases in all organs and tissues and has …

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease of unknown cause
characterized by relentless scarring of the lung parenchyma leading to reduced quality of life …

Fibrosis is a disorder characterized by a qualitative and quantitative alteration of the
deposition of extracellular matrix with accumulation of mesenchymal cells in replacement of …

4. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. NHLBI workshop summary:
pharmacological therapy for idiopathic pulmonary fibrosis: past, present and future. Am J …

In the past several years, significant progress in many aspects of pulmonary fibrosis
research has been made. Among them, the finding that a variety of cytokines play important …

Idiopathic pulmonary fibrosis (IPF) is characterized by an increased oxidant burden and by a
deficiency of glutathione, a major antioxidant, in the lung epithelial lining fluid (ELF) …

The role of inflammation in idiopathic pulmonary fibrosis (IPF) is controversial. If
inflammation were critical to the disease process, lung pathology would demonstrate an …